By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Development of endocrine resistance remains a challenge in the management of HR-positive HER2-negative breast cancer (HR+ HER2- BC). Alterations in PI3K
By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Development of endocrine resistance remains a challenge in the management of HR-positive HER2-negative breast cancer (HR+ HER2- BC). Alterations in PI3K
By Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center Data from two phase III trials showed that adding immune checkpoint inhibition in the neoadjuvant setting in HR positive breast cancer was
By: Dr. Anam Kamal Ascension Providence Hospital; Michigan The standard of care for such patients is platinum-based doublet chemotherapy. In May 2021, the FDA granted accelerated approval to Amivantamab for the treatment
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On October 27, the U.S. Food and Drug Administration approved toripalimab-tpzi (Loqtorzi) in combination with chemotherapy for adult patients with metastatic or locally advanced nasopharyngeal carcinoma